Last reviewed · How we verify
Allogeneic Mesenchymal Stromal Cell
At a glance
| Generic name | Allogeneic Mesenchymal Stromal Cell |
|---|---|
| Also known as | Allogeneic bone marrow-derived mesenchymal stromal cells, Allogeneic bone marrow-derived mesenchymal stem cells, Allogeneic BM-MSC |
| Sponsor | Martin Teraa, MD, PhD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS (PHASE2)
- Pilot Study of Radiation-Induced Xerostomia Treatment With Allogeneic Mesenchymal Stromal Stem Cells (PHASE1)
- Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease (PHASE1)
- Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study (PHASE1, PHASE2)
- ASCs in Recently Diagnosed Non-ischemic Heart Failure (PHASE2)
- A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects (PHASE1)
- Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease (PHASE2)
- Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allogeneic Mesenchymal Stromal Cell CI brief — competitive landscape report
- Allogeneic Mesenchymal Stromal Cell updates RSS · CI watch RSS
- Martin Teraa, MD, PhD portfolio CI